Last reviewed · How we verify
Dupilumab therapy
Dupilumab is a monoclonal antibody developed by the National Medical Research Center for Children's Health in the Russian Federation. It is not approved by the FDA and is primarily used for treating atopic dermatitis and asthma. The drug works by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of type 2 inflammation. Despite its lack of FDA approval, it has shown promise in clinical trials and is being evaluated for additional indications such as chronic rhinosinusitis with nasal polyps. Safety concerns include common side effects like injection site reactions and conjunctivitis, but no boxed warnings or major contraindications have been reported.
At a glance
| Generic name | Dupilumab therapy |
|---|---|
| Sponsor | National Medical Research Center for Children's Health, Russian Federation |
| Drug class | Monoclonal Antibody |
| Target | IL-4Rα |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (PHASE3)
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
- Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
- A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (PHASE2)
- The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (PHASE3)
- A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
- A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: